HYBRIDIZE THERAPEUTICS

At Hybridize Therapeutics, we are developing antisense oligonucleotides that target the Achilles' heel of polyomaviruses. This is the only therapeutic in development that is a direct acting anti-viral which works intra-cellular and protects the cells from within. It is designed to target the viral mRNA and therefore provides for low off-target effects... Hybridize is a spin-off from the Leiden University Medical Center (LUMC). The LUMC has been a frontrunner in both Nephrology & RNA-based medicine. Prof. Dr. Willem Kolff, inventor of the kidney dialysis machine (1943), studied Medicine at the LUMC, while Prof. Dr. Jacques van Boom played a pivotal pioneering role in oligonucleotide chemistry (1975)... Currently, Hybridize focuses on its platform technology that improves delivery of siRNA with an initial focus on the proximal tubule epithelial cells (PTECs). This technology provides an enormous opportunity that has been lacking in this field of the industry: successful deployment of..

Also known as: Hybridize

Primary location: Oegstgeest Netherlands